{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:27:34Z","timestamp":1791196054578,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.10.027","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T20:35:59Z","timestamp":1447187759000},"page":"586-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults"],"prefix":"10.1016","volume":"34","author":[{"given":"Marilia","family":"Santini-Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u00e7ara","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdilea","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia A.","family":"Ciol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2015.10.027_bib0270","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"9859","key":"10.1016\/j.vaccine.2015.10.027_bib0275","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0035-9203(85)90391-8","article-title":"Immunity after treatment of human Schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses","volume":"79","author":"Butterworth","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-4894(83)90002-4","article-title":"Schistosoma and related genera: acquired resistance in mice","volume":"55","author":"Dean","year":"1983","journal-title":"Exp Parasitol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.027_bib0290","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pt.2005.01.001","article-title":"Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?","volume":"21","author":"Bergquist","year":"2005","journal-title":"Trends Parasitol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.027_bib0295","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0169-4758(97)01207-6","article-title":"Schistosomiasis vaccine: research to development","volume":"14","author":"Bergquist","year":"1998","journal-title":"Parasitol Today"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.027_bib0300","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1128\/IAI.68.5.2797-2803.2000","article-title":"Human immune responses to Schistosoma mansoni vaccine candidate antigens","volume":"68","author":"Ribeiro de Jesus","year":"2000","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.027_bib0305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0001-706X(03)00195-5","article-title":"In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens","volume":"88","author":"Al-Sherbiny","year":"2003","journal-title":"Acta Trop"},{"issue":"7","key":"10.1016\/j.vaccine.2015.10.027_bib0310","doi-asserted-by":"crossref","first-page":"e1704","DOI":"10.1371\/journal.pntd.0001704","article-title":"Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis","volume":"6","author":"Riveau","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2015.10.027_bib0315","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1016\/S0021-9258(18)92995-9","article-title":"A 14kDa Schistosoma mansoni polypepetide is homologous to a gene family of fatty acid binding proteins","volume":"266","author":"Moser","year":"1991","journal-title":"J Biol Chem"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2015.10.027_bib0320","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.actatropica.2008.09.002","article-title":"The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine","volume":"108","author":"Tendler","year":"2008","journal-title":"Acta Trop"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.027_bib0325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/CMR.00046-07","article-title":"Current status of vaccines for schistosomiasis","volume":"21","author":"McManus","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.027_bib0330","first-page":"137","article-title":"Schistosomiasis vaccines: literature review and current status","volume":"4","author":"Ismail","year":"2011","journal-title":"PUJ"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.027_bib0335","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1590\/S0074-02761995000200022","article-title":"Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multivalent anti-helminth vaccine","volume":"90","author":"Tendler","year":"1995","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0340","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1073\/pnas.93.1.269","article-title":"A Schistosoma mansoni fatty acid binding protein, Sm14, is the potential basis of a dual-purpose anti-helmintic vaccine","volume":"93","author":"Tendler","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.027_bib0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0264-410X(03)00300-1","article-title":"An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis","volume":"22","author":"Vilar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-3024.2003.00619.x","article-title":"Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14","volume":"25","author":"Almeida","year":"2003","journal-title":"Parasite Immunol"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2015.10.027_bib0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1590\/S0074-02762001000900019","article-title":"r-Sm14-pRSETA efficacy in experimental animals","volume":"96","author":"Ramos","year":"2001","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"4","key":"10.1016\/j.vaccine.2015.10.027_bib0360","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbapap.2008.12.010","article-title":"Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate","volume":"1794","author":"Ramos","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0365","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","article-title":"A synthetic adjuvant to enhance and expand immune responses to influenza vaccines","volume":"5","author":"Coler","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0370","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0375","unstructured":"Florida Biologix\u00ae, 2006. Available at: http:\/\/www.floridabiologix.ufl.com (last accessed January 2014)."},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.027_bib0380","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jir769","article-title":"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults","volume":"205","author":"Behzad","year":"2012","journal-title":"J Infect Dis"},{"issue":"Aug (1)","key":"10.1016\/j.vaccine.2015.10.027_bib0385","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.colsurfb.2008.03.003","article-title":"Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions","volume":"65","author":"Fox","year":"2008","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.colsurfb.2009.08.022","article-title":"Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations","volume":"75","author":"Anderson","year":"2010","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0395","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","article-title":"Enhanced humoral and Type 1 cellular immune responses with Fluzone\u00ae adjuvanted with a synthetic TLR4 agonist formulated in an emulsion","volume":"27","author":"Baldwin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0400","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","article-title":"A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular responses against GMZ2\u2014a GLURP-MSP3 fusion protein malaria vaccine candidate","volume":"29","author":"Lousada_Dietrich","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0405","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2015.10.027_bib0410","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0415","unstructured":"PPD Development LLC, 1985. Available at: http:\/\/www.ppdi.com\/(last accessed January 2014)."},{"key":"10.1016\/j.vaccine.2015.10.027_bib0420","unstructured":"Invitare Pesquisa Cl\u00ednica, 1998. Available at: http:\/\/invitare.com.br (last accessed January 2014)."},{"key":"10.1016\/j.vaccine.2015.10.027_bib0425","unstructured":"ClinicalTrials National Institute of Health, 2000. Available at: http:\/\/www.clinicaltrials.gov (last accessed January 2014)."},{"key":"10.1016\/j.vaccine.2015.10.027_bib0430","unstructured":"International Clinical Studies Support Center ICSSC. http:\/\/www.icssc.org\/Documents\/Resources\/ICTDR AE Manual February 6 2003 final.pdf (last accessed January 2012)."},{"key":"10.1016\/j.vaccine.2015.10.027_bib0435","unstructured":"Food and Drug Administration FDA, 1906. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm074775.htm (last accessed January 2012)."},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.027_bib0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1373\/clinchem.2009.127803","article-title":"The ELISA enzyme-linked immunosorbent assay","volume":"56","author":"Engvall","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0445","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.vaccine.2015.10.027_bib0450","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00281-012-0354-4","article-title":"Th2 responses in schistosomiasis","volume":"34","author":"Fairfax","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.027_bib0455","doi-asserted-by":"crossref","first-page":"e3164","DOI":"10.1371\/journal.pntd.0003164","article-title":"Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis","volume":"8","author":"Mbanefo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"Oct (4\u20135)","key":"10.1016\/j.vaccine.2015.10.027_bib0460","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0171-2985(11)80450-X","article-title":"The role of cytokines in the formation of the schistosome egg granuloma","volume":"191","author":"Boros","year":"1994","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0465","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4615-5355-7_9","article-title":"The initiation and function of Th2 responses during infection with Schistosoma mansoni","volume":"452","author":"Pearce","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0470","first-page":"192","article-title":"Antiparasitic effects of tumour necrosis factor in vivo and in vitro","volume":"131","author":"Playfair","year":"1987","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0475","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/eji.1830260628","article-title":"Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection","volume":"26","author":"Grogan","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.0105-2896.2004.00191.x","article-title":"Helminth parasites\u2014masters of regulation","volume":"201","author":"Maizels","year":"2004","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2015.10.027_bib0485","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0166-6851(99)00149-8","article-title":"Gender-specific gene expression in Brugia malayi","volume":"104","author":"Michalski","year":"1999","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0490","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-3024.2000.00311.x","article-title":"Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans","volume":"22","author":"Scott","year":"2000","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0495","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1017\/S0031182010001216","article-title":"Acquired immune heterogeneity and its sources in human helminth infection","volume":"138","author":"Bourke","year":"2011","journal-title":"Parasitology"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.027_bib0500","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.173.1.159","article-title":"Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth. Schistosoma mansoni","volume":"173","author":"Pearce","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0505","first-page":"4","article-title":"Immunology of parasitic helminth infections","volume":"82","author":"MacDonald","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0510","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/eji.1830211106","article-title":"Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels","volume":"21","author":"Rihet","year":"1991","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.10.027_bib0515","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-3024.2010.01270.x","article-title":"Differential recognition of Schistosoma haematobium adult worm antigens by the human antibodies IgA, IgE, IgG1 and IgG4","volume":"33","author":"Mutapi","year":"2011","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0520","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1385\/MB:21:2:129","article-title":"The development and use of vaccine adjuvants","volume":"21","author":"Edelman","year":"2002","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0525","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a tuberculosis vaccine","volume":"188","author":"Baldwin","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.10.027_bib0530","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis","volume":"2","author":"Bertholet","year":"2010","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:26:08Z","timestamp":1653510368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15014425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15014425"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}